Nilotinib: selective inhibitor as second-line therapy

Massimo Breccia

DOI: https://doi.org/10.7175/cmi.v4i6S.1096

Full Text

PDF

Statistics

Abstract: 372 views
PDF: 255 views

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.